Company news

Clinuvel Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Media Release - CLINUVEL to Trial Innovative Drug in Stroke

October 27, 2020

Australian TGA approves SCENESSE

October 27, 2020

Trading Halt

October 26, 2020

Media Release - First patient dosed in SCENESSE DNA Repair

September 14, 2020

CLINUVEL progresses innovative DNA Repair Program

September 10, 2020

Corporate Presentation - 2020 Full Year Results

August 27, 2020

CLINUVEL Declares Full Year Dividend

August 27, 2020

CLINUVEL Full Year Results

August 27, 2020

CLINUVEL Corporate Update

July 30, 2020

Media Release - SCENESSE to be prescribed in China

April 22, 2020

TGA Priority Registration Pathway for SCENESSE

October 30, 2019

FDA Grants Marketing Approval for SCENESSE

October 8, 2019

CLINUVEL renews CEO Employment Agreement

October 6, 2019

FDA Clarifies SCENESSE PDUFA Date

October 2, 2019

Dividend/Distribution - CUV

August 28, 2019

Appendix 4E and Preliminary Financial Report Reissued

August 28, 2019

CLINUVEL declares Full Year Dividend

August 28, 2019

US FDA extends PDUFA date for SCENESSE

June 2, 2019

US FDA sets PDUFA date for SCENESSE

January 9, 2019

CUV103 Singaporean Phase II vitiligo study results

December 18, 2018

Appeal Upheld Against NICE Recommendation in England

October 9, 2018

S&P DJI Announces September 2018 Quarterly Rebalance

September 6, 2018

US FDA Update

September 4, 2018

CLINUVEL completes SCENESSE FDA Filing

June 25, 2018

NICE maintains position not to recommend SCENESSE

May 22, 2018

CLINUVEL Regulatory Update

May 13, 2018

CLINUVEL to take 100% ownership of VALLAURIX joint venture

May 1, 2018

CLINUVEL hosts European EPP Expert Meeting

March 18, 2018

Preliminary assessment received from NICE

December 20, 2017

CLINUVEL provides update on SCENESSE FDA filing

September 18, 2017

Preliminary Final Report

August 30, 2017

Amended Appendix 4C - quarterly

July 31, 2017

NICE England Update on SCENESSE

May 1, 2017

CLINUVEL reaches agreement on German SCENESSE pricing

April 12, 2017

CLINUVEL agrees with FDA on New Drug Application timelines

November 8, 2016

SCENESSE - NICE England Update

October 17, 2016

FDA Schedules Pre-NDA Meeting for SCENESSE

October 12, 2016

Clinuvel completes combination therapy pre-clinical study

August 3, 2016

FDA accept SCENESSE clinical data package for NDA submission

July 18, 2016

FDA awards SCENESSE Fast Track designation for EPP treatment

July 5, 2016

SCENESSE launched in Europe

June 22, 2016

SCENESSE Treatment in Europe

May 18, 2016

SCENESSE attains breakthrough European Market Authorisation

March 30, 2016

US patent for alpha-MSH and analogues

March 30, 2016

Patent to assist drug as potential skin cancer preventative

March 30, 2016

Clinuvel to evaluate SCENESSE as therapy in vitiligo

March 30, 2016

Clinuvel - strategic focus of final regulatory program

March 30, 2016

Clinuvel selects leading US manufacturing partner

March 30, 2016

Clinuvel reports positive results in Phase III EPP trial

March 30, 2016

FDA provides positive guidance on Clinuvel`s EPP program

March 30, 2016

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 62 decks. Every deck is listed under its year.